文献速递心脑血管急症

氯吡格雷联合阿司匹林在发病24至72小时内启动治疗轻度缺血性卒中:INSPIRES随机临床试验亚组分析

Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-09-03
一句话结论轻度缺血性卒中或TIA患者在症状出现后72小时内启动氯吡格雷联合阿司匹林,相比单用阿司匹林可降低90天新发卒中风险,中重度出血风险相似。

该研究为INSPIRES随机临床试验的亚组分析,纳入中国222家医院6100例急性轻度缺血性卒中或TIA患者,按症状出现至随机化时间分为≤24小时、>24至≤48小时、>48至72小时三组,比较氯吡格雷联合阿司匹林与单用阿司匹林对90天新发卒中的影响。结果显示,在>48至72小时组,联合治疗组新发卒中风险显著低于阿司匹林组(5.8% vs 8.2%;HR,0.70 [95% CI,0.53-0.94]),在>24至48小时组(7.6% vs 8.9%;HR,0.85 [95% CI,0.65-1.12])和≤24小时组(11.5% vs 13.4%;HR,0.83 [95% CI,0.55-1.25])方向一致但未达统计学显著,交互作用P=0.38。中重度出血在三组间交互作用P=0.92。作者结论认为,在症状出现后72小时内启动氯吡格雷联合阿司匹林双联抗血小板治疗,患者获益一致,中重度出血风险增加相似。

要点

  • 在>48至72小时时间窗内启动氯吡格雷联合阿司匹林,相比单用阿司匹林可显著降低90天新发卒中风险(5.8% vs 8.2%;HR,0.70 [95% CI,0.53-0.94])。
  • 在≤24小时(11.5% vs 13.4%;HR,0.83 [95% CI,0.55-1.25])和>24至48小时(7.6% vs 8.9%;HR,0.85 [95% CI,0.65-1.12])时间窗内,联合治疗组新发卒中风险数值上较低但未达统计学显著,交互作用P=0.38。
  • 中重度出血风险在各时间窗内联合治疗组与阿司匹林组相比均无统计学显著差异(交互作用P=0.92)。
  • 作者结论建议:轻度缺血性卒中或TIA患者应在症状出现后72小时内接受氯吡格雷联合阿司匹林双联抗血小板治疗。

适用人群与场景

  • 急性轻度缺血性卒中或TIA患者,来自中国222家医院,纳入INSPIRES随机临床试验。
  • 按症状出现至随机化时间分为三组:≤24小时、>24至≤48小时、>48至72小时。

处置流程与药物剂量

  • 氯吡格雷联合阿司匹林组:氯吡格雷第1天负荷剂量300 mg,第2至90天每日75 mg;阿司匹林第1天100至300 mg,第2至90天每日100 mg。
  • 阿司匹林单药组:阿司匹林第1天100至300 mg,第2至90天每日100 mg。
  • 所有患者在症状出现后72小时内启动治疗。

研究设计与关键结果

  • 研究类型:INSPIRES随机临床试验的亚组分析,该试验为双盲、安慰剂对照、多中心、2×2析因随机临床试验,在中国222家医院开展,时间为2018年9月17日至2022年10月15日。
  • 样本量:共纳入6100例患者(氯吡格雷-阿司匹林组3050例,阿司匹林组3050例);中位年龄65岁(IQR,57-71岁),男性3915例(64.2%);随访90天。
  • 主要终点(90天内新发卒中):在≤24小时组,氯吡格雷-阿司匹林组97/783例(12.4%)发生卒中;在>24至48小时组,211/2552例(8.3%);在>48至72小时组,193/2765例(7.0%)。
  • 在>48至72小时组,氯吡格雷-阿司匹林组新发卒中风险低于阿司匹林组(5.8% vs 8.2%;HR,0.70 [95% CI,0.53-0.94])。
  • 在>24至48小时组,氯吡格雷-阿司匹林组新发卒中风险与阿司匹林组相比(7.6% vs 8.9%;HR,0.85 [95% CI,0.65-1.12]),未达统计学显著。
  • 在≤24小时组,氯吡格雷-阿司匹林组新发卒中风险与阿司匹林组相比(11.5% vs 13.4%;HR,0.83 [95% CI,0.55-1.25]),未达统计学显著;交互作用P=0.38。
  • 中重度出血:在>48至72小时组,氯吡格雷-阿司匹林组12例(0.9%)vs 阿司匹林组6例(0.4%)(HR,2.00 [95% CI,0.73-5.43]);在>24至48小时组,9例(0.7%)vs 4例(0.3%)(HR,2.25 [95% CI,0.68-7.39]);在≤24小时组,6例(1.5%)vs 3例(0.8%)(HR,1.57 [95% CI,0.36-6.83]);交互作用P=0.92。

证据类型、等级与局限

  • 证据类型:随机临床试验(INSPIRES)的亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为:轻度缺血性卒中或TIA患者应在症状出现后72小时内接受氯吡格雷联合阿司匹林双联抗血小板治疗。

指南或共识出处

  • INSPIRES随机临床试验(ClinicalTrials.gov Identifier: NCT03635749)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Prior trials showed that dual antiplatelet therapy could reduce the risk of early new stroke in patients with acute mild ischemic stroke or transient ischemic attack (TIA) within 24 hours of symptom onset. However, it is currently uncertain whether dual antiplatelet therapy can reduce the risk of early new stroke in patients with a more delayed initiation time window.

OBJECTIVE: To evaluate the efficacy and safety of clopidogrel and aspirin among patients with mild ischemic stroke or TIA when initiated within 24 hours, from more than 24 hours to 48 hours, and from more than 48 hours to 72 hours.

DESIGN, SETTING, AND PARTICIPANTS: The Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis randomized clinical trial was a double-blind, placebo-controlled, multicenter, 2-by-2 factorial randomized clinical trial conducted at 222 hospitals in China from September 17, 2018, to October 15, 2022. All patients with acute mild ischemic stroke and TIA were included in this subgroup analysis and categorized into 3 groups according to time from symptom onset to randomization (group 1: ≤24 hours; group 2: >24 to ≤48 hours; and group 3: >48 to 72 hours). Patients were followed up for 90 days.

INTERVENTIONS: All patients received clopidogrel combined with aspirin (clopidogrel 300 mg loading dose on day 1, followed by 75 mg daily on days 2 to 90, and aspirin 100 to 300 mg on the first day and then 100 mg daily for days 2 to 90) or aspirin alone (100 to 300 mg on day 1 and then 100 mg daily for days 2 to 90) within 72 hours after symptom onset.

MAIN OUTCOMES AND MEASURES: The primary outcome was new stroke (ischemic or hemorrhagic) within 90 days. The primary safety outcome was moderate-to-severe bleeding, according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria.

RESULTS: This analysis included a total of 6100 patients (3050 in the clopidogrel-aspirin group and 3050 in the aspirin group). The median age was 65 years (IQR, 57-71 years), and 3915 patients (64.2%) were male. In the population with time to randomization of 24 hours or less, stroke occurred in the next 90 days in 97 of 783 patients (12.4%); among those randomized from more than 24 hours to 48 hours, in 211 of 2552 patients (8.3%) among those randomized from more than 24 hours to 48 hours, and in 193 of 2765 patients (7.0%). The clopidogrel-aspirin group had a lower risk of new stroke within 90 days compared with the aspirin alone group both in patients with time to randomization of from 48 to 72 hours (5.8% vs 8.2%; hazard ratio [HR], 0.70 [95% CI, 0.53-0.94]), of more than 24 to 48 hours (7.6% vs 8.9%; HR, 0.85 [95% CI, 0.65-1.12]), and of 24 hours or less (11.5% vs 13.4%; HR, 0.83 [95% CI, 0.55-1.25]) (P = .38 for interaction). Among those with time to randomization of more than 48 to 72 hours, moderate-to-severe bleeding occurred in 12 patients (0.9%) in the clopidogrel-aspirin group and in 6 patients (0.4%) in the aspirin-alone group (HR, 2.00 [95% CI, 0.73-5.43]), while moderate-to-severe bleeding in those with time to randomization of more than 24 hours to 48 hours occurred in 9 patients (0.7%) in the clopidogrel-aspirin group and in 4 patients (0.3%) in the aspirin-alone group (HR, 2.25 [95% CI, 0.68-7.39]) and in those with time to randomization of within 24 hours, occurred in 6 patients (1.5%) in the clopidogrel-aspirin group and in 3 patients (0.8%) in the aspirin-alone group (HR, 1.57 [95% CI, 0.36-6.83]) (P = .92 for interaction).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of antiplatelet therapy in China, patients with mild ischemic stroke or TIA had consistent benefit from dual antiplatelet therapy with clopidogrel and aspirin vs aspirin alone when initiated within 72 hours after symptom onset, with a similar increase in the risk of moderate-to-severe bleeding. Patients should receive dual antiplatelet therapy with clopidogrel and aspirin within 72 hours after symptom onset.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03635749.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Liu Y, Zhao J, Gao Y, et al. Clopidogrel and Aspirin Initiated Between 24 to 72 Hours for Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39240565. doi:10.1001/jamanetworkopen.2024.31938

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。